Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Portal vein thrombosis (PVT) in patients with liver cirrhosis may be due to neoplastic growth or non-neoplastic causes.

• Treating PVT with anticoagulation in liver cirrhosis is difficult to be established but may be of great benefit in acute symptomatic PVT.

• The ultimate goal is complete recanalization of the portal vein without inducing major bleeding, abnormal liver function tests or increased mortality.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Acute non-neoplastic portal vein thrombosis

• Compensated cirrhosis (Child class A-B)

• The onset of PVT is within 1 week.

Exclusion Criteria:

• Decompensated liver disease

• Bleeding tendency or recent bleeding event as bleeding peptic ulcer or oesophageal varices

• Neoplastic invasion of the portal vein

• Renal impairment with the creatinine clearance ≤ 30 ml/min

• Pregnancy and breastfeeding

• Hypersensitivity to rivaroxaban

• Concomitant treatment with another anticoagulant

• Concomitant use of clopidogrel.